# C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

> **NCT07729826** · PHASE2 · NOT_YET_RECRUITING · sponsor: **AbelZeta Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Lupus Nephritis (LN)
- Systemic Lupus Erythematosus (SLE)
- Autoimmune Diseases

## Interventions

- **DRUG:** C-CAR168

## Key facts

- **NCT ID:** NCT07729826
- **Lead sponsor:** AbelZeta Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729826, "C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07729826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*